WO2004002475A1 - Sustained release tablet containing indapamide - Google Patents

Sustained release tablet containing indapamide Download PDF

Info

Publication number
WO2004002475A1
WO2004002475A1 PCT/PL2002/000056 PL0200056W WO2004002475A1 WO 2004002475 A1 WO2004002475 A1 WO 2004002475A1 PL 0200056 W PL0200056 W PL 0200056W WO 2004002475 A1 WO2004002475 A1 WO 2004002475A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
indapamide
total mass
amount
sustained release
Prior art date
Application number
PCT/PL2002/000056
Other languages
French (fr)
Inventor
Katarzyna Jureczek
Original Assignee
Pliva Kraków, Zaklady Farmaceutyczne S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Kraków, Zaklady Farmaceutyczne S.A. filed Critical Pliva Kraków, Zaklady Farmaceutyczne S.A.
Priority to EP02765720A priority Critical patent/EP1517683B1/en
Priority to US10/518,386 priority patent/US7553499B2/en
Priority to DE60220551T priority patent/DE60220551T2/en
Publication of WO2004002475A1 publication Critical patent/WO2004002475A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a sustained release tablet containing indapamide and the process of manufacturing sustained release tablet containing indapamide, known medicinal product of diuretic activity administered in the therapy of primary hypertension.
  • a process for the preparation of an indapamide matrix tablet known from the patent No. EP 519820 is based on that there are used both a moist granulation technique and a direct compression technique, comprising the steps as follows. First, indapamide, polyvidone and lactose are mixed, then moistened with an aqueous-alcoholic solution to yield a moist mass which is then granulated, dried and then graded so as to obtain a granulate whose physical characteristics allow good filling of the moulds of a rapid compression machine.
  • the obtained granulate is mixed with methylhydoxypropylcellulose and lubricated with magnesium stearate and colloidal silica.
  • the final step is compression of the lubricated mixture in a rotary compression machine, so as to obtain tablets having a hardness of approximately from 60 do 75 N.
  • the tablet for the sustained release containing indapamide contains indapamide in the amount 1.5 to 2.5% of the total mass of the tablet, lactose monohydrate in the amount of 30 to 80% of the total mass of the tablet, copovidone in the amount of 2 to 10% of the total mass of the tablet, hypromellose in the amount of 20 to 65% of the total mass of the tablet and lubricants in the amount of 0.1 to 5% of the total mass of the tablet.
  • the aim of the use of copovidone is to bind all tablet components.
  • Hypromellose modifies the release of the active ingredient, which is indapamide.
  • Magnesium stearate or/and anhydrous colloidal silica are used as the lubricants.
  • Hypromellose viscosity is between 1.000 to 20.000 cP.
  • the process of manufacturing the sustained release tablet containing indapamide consists in mixing indapamide with lactose monohydrate and copovidone. Then, the mixture is moistened by purified water and granulated. The obtained granulate is then dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine.
  • the aim of the invention was to simplify the process of manufacturing the sustained release tablet containing indapamide. Additionally, it allowed replacing alcohol with water what improved safety of the manufacturing process and reduced its impact on the environment.
  • wet granulate is rubbed through the screen of 2.5 mm mesh and dried in the fluidal drier in the temperature 40°C to humidity content below 1 %.
  • the dried granulate is sieved through the screen 1.2 mm mesh.
  • step mixing of the granulate with the rest of components is performed in the rotary mixer with speed 20 rpm.
  • the granulation process is performed within 4 minutes with the main agitator speed 400 ⁇ m and the side agitator speed 800 ⁇ m.
  • wet granulate is rubbed through a screen 2.5 mm mesh and is dried in the fluidal drier in the temperature 40°C to humidity content below 1 %.
  • the dried granulate is sieved through the screen 1.2 mm mesh.
  • the mixing granulate with the rest of components is performed in the rotary mixer with the speed 20 ⁇ m.
  • 662 g of granulate with 330 g of hypromellose is poured and mixed within 10 minutes.
  • 662 g of the granulate is added and mixed within 10 minutes, after which 330 g of hypromellose together with 6 g of colloidal silica is added and mixed within 15 minutes, and next 10 g of magnesium stearate is added and mixed within 5 minutes.
  • the invention may be used in the industrial process of manufacturing sustained release tablets containing indapamide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a sustained release tablet containing indapamide and the process of manufacturing sustained release tablet containing indapamide. The tablet contains indapamide in the amount of 1.5 to 2.5% of the total mass of the tablet, lactose monohydrate in the amount of 30 to 80% of the total mass of the tablet, copovidone in the amount of 2 to 10% of the total mass of the tablet, hypromellose in the amount of 20 to 65% of the total mass of the tablet and lubricants in the amount of 0.1 to 5% of the total mass of the tablet. The process of manufacturing the sustained release tablet consists in mixing of indapamide with lactose monohydrate and copovidone and then, the mixture is moistened by purified water and the granulation process of it is performed. Next the granulate is dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine. (4 claims)

Description

Sustained release tablet containing indapamide
The present invention relates to a sustained release tablet containing indapamide and the process of manufacturing sustained release tablet containing indapamide, known medicinal product of diuretic activity administered in the therapy of primary hypertension.
From a specification of the patent No: EP 519820 it is known a sustained release matrix tablet of indapamide and a process of its manufacturing. Sustained release is controlled by the use of methylhydroxypropylcellulose and polyvidone, the percentages of which are from 30 to 50% and from 2 to 10%, respectively, of the total mass of the tablet. The percentages of the cellulose and polyvidone compounds permit the sustained release of indapamide in a manner that is linear for a period of at least eight hours and the release of 50% of the total quantity of indapamide within a period of from 5 to 14 hours. Additionally, the percentages of cellulose and polyvidone compounds permit the sustained release of indapamide to give blood levels in humans of from 20 to 80 ng/ml at most after administration of the tablet by the oral route. A process for the preparation of an indapamide matrix tablet known from the patent No. EP 519820 is based on that there are used both a moist granulation technique and a direct compression technique, comprising the steps as follows. First, indapamide, polyvidone and lactose are mixed, then moistened with an aqueous-alcoholic solution to yield a moist mass which is then granulated, dried and then graded so as to obtain a granulate whose physical characteristics allow good filling of the moulds of a rapid compression machine. The obtained granulate is mixed with methylhydoxypropylcellulose and lubricated with magnesium stearate and colloidal silica. The final step is compression of the lubricated mixture in a rotary compression machine, so as to obtain tablets having a hardness of approximately from 60 do 75 N.
According to the invention, the tablet for the sustained release containing indapamide contains indapamide in the amount 1.5 to 2.5% of the total mass of the tablet, lactose monohydrate in the amount of 30 to 80% of the total mass of the tablet, copovidone in the amount of 2 to 10% of the total mass of the tablet, hypromellose in the amount of 20 to 65% of the total mass of the tablet and lubricants in the amount of 0.1 to 5% of the total mass of the tablet. The aim of the use of copovidone is to bind all tablet components. Hypromellose modifies the release of the active ingredient, which is indapamide.
Magnesium stearate or/and anhydrous colloidal silica are used as the lubricants.
Hypromellose viscosity is between 1.000 to 20.000 cP.
According to the invention the process of manufacturing the sustained release tablet containing indapamide consists in mixing indapamide with lactose monohydrate and copovidone. Then, the mixture is moistened by purified water and granulated. The obtained granulate is then dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine.
The aim of the invention was to simplify the process of manufacturing the sustained release tablet containing indapamide. Additionally, it allowed replacing alcohol with water what improved safety of the manufacturing process and reduced its impact on the environment.
Examples of the invention are presented below: Example I.
25 g of indapamide and 225 g of lactose monohydrate is mixed manually, the mixture is poured into a granulate-mixer together with 487 g of lactose monohydrate and is mixed within 1 minute with the main agitator speed 200 rpm.
Then 487 g of lactose monohydrate and 60 g of copovidone is added and all components are mixed for 1 minute with the main agitator speed 200 rpm and then with the main agitator speed 200 rpm and the side agitator speed 400 rpm.
To the prepared mixture 100 g of purified water is added within 1 minute with the main agitator speed 200 rpm and the side agitator speed 400 rpm. Then, the granulation process is performed within 4 minutes with the main agitator speed 400 rpm and side agitator speed 800 rpm.
Wet granulate is rubbed through the screen of 2.5 mm mesh and dried in the fluidal drier in the temperature 40°C to humidity content below 1 %. The dried granulate is sieved through the screen 1.2 mm mesh.
In the following step mixing of the granulate with the rest of components is performed in the rotary mixer with speed 20 rpm.
Into rotary mixer 642 g of granulate with 350 g of hypromellose is poured and mixed within 10 minutes, after which 642 g of granulate is added and is mixed within 10 minutes. Then, 350 g of hypromellose is added with 6 g of colloidal silica and is mixed within 15 minutes, after which 10 g of magnesium stearate is added and mixed within 5 minutes.
Finally tableting process of the prepared mixture is performed.
Example II.
25 g of indapamide and 225 g of lactose monohydrate is mixed manually and next the mixture is poured into granulate-mixer together with 507 g of lactose monohydrate and is mixed within 1 minute with the main agitator speed 200 rpm.
Then 507 g of lactose monohydrate and 60 g of copovidone is added and all components are mixed within 1 minute with the main agitator speed 200 m and 1 minute with the main agitator speed 200 m and the side agitator speed 400 φm.
To the mixture obtained in such way 100 g of purified water is dosed within 1 minute with the main agitator speed 200 φm and the side agitator speed 400 rpm,
Next the granulation process is performed within 4 minutes with the main agitator speed 400 φm and the side agitator speed 800 φm.
Wet granulate is rubbed through a screen 2.5 mm mesh and is dried in the fluidal drier in the temperature 40°C to humidity content below 1 %. The dried granulate is sieved through the screen 1.2 mm mesh.
In the following step the mixing granulate with the rest of components is performed in the rotary mixer with the speed 20 φm. Into rotary mixer 662 g of granulate with 330 g of hypromellose is poured and mixed within 10 minutes. Then, 662 g of the granulate is added and mixed within 10 minutes, after which 330 g of hypromellose together with 6 g of colloidal silica is added and mixed within 15 minutes, and next 10 g of magnesium stearate is added and mixed within 5 minutes.
Finally tableting process of the prepared mixture is performed.
The invention may be used in the industrial process of manufacturing sustained release tablets containing indapamide.

Claims

Claims
1. Sustained release tablet containing indapamide, characterized in that the tablet contains indapamide in the amount 1.5 to 2.5 % of the total mass of the tablet, lactose monohydrate in the amount 30 to 80 % of the total mass of the tablet, copovidon in the amount of 2 to 10 % of
> the total mass of the tablet, hypromellose in the amount of 20 to 65 % of the total mass of the tablet and lubricants in the amount of 0.1 to 5 % of the total mass of the tablet.
2. Tablet according to claim 1, characterized in that as the lubricants it contains magnesium stearate or/and anhydrous colloidal silica.
0 3. Tablet according to claim 1, characterized in that hypromellose viscosity is from 1.000 to 20.000 eP.
4. Process of manufacturing sustained release tablet containing indapamide, characterized in that indapamide is mixed with lactose monohydrate and copovidone and then the mixture is moisturised by 5 purified water and its granulation is performed after which the granulate is dried, cooled, mixed with hypromellose and lubricants and compressed in tableting machine.
PCT/PL2002/000056 2002-07-01 2002-07-24 Sustained release tablet containing indapamide WO2004002475A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02765720A EP1517683B1 (en) 2002-07-01 2002-07-24 Sustained release tablet containing indapamide
US10/518,386 US7553499B2 (en) 2002-07-01 2002-07-24 Sustained release tablet containing indapamide
DE60220551T DE60220551T2 (en) 2002-07-01 2002-07-24 TABLETS WITH DELAYED ACTIVE INGREDIENT CONTAINING INDAPAMID

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.354823 2002-07-01
PL354823A PL193976B1 (en) 2002-07-01 2002-07-01 Prolonged effect containing indapamide and method of manufacture of prolonged effect tablets containing indapamide

Publications (1)

Publication Number Publication Date
WO2004002475A1 true WO2004002475A1 (en) 2004-01-08

Family

ID=29997631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2002/000056 WO2004002475A1 (en) 2002-07-01 2002-07-24 Sustained release tablet containing indapamide

Country Status (6)

Country Link
US (1) US7553499B2 (en)
EP (1) EP1517683B1 (en)
AT (1) ATE363903T1 (en)
DE (1) DE60220551T2 (en)
PL (1) PL193976B1 (en)
WO (1) WO2004002475A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074884A2 (en) * 2004-01-30 2005-08-18 Krka, Tovarna Zdravil, D.D. Novo Mesto Sustained release pharmaceutical composition of indapamide
EP1669062A1 (en) 2004-12-07 2006-06-14 Les Laboratoires Servier Extended release indapamide tablets and their process of manufacture
WO2006069705A1 (en) * 2004-12-23 2006-07-06 Merckle Gmbh Directly pressed indapamide tablets with delayed release of the active substance

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773500B (en) * 2010-02-09 2012-05-23 施慧达药业集团(吉林)有限公司 Antihypertensive medicinal composition
US8597683B2 (en) * 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
CN103142529B (en) * 2013-03-07 2013-12-25 宁夏康亚药业有限公司 Indapamide sustained-release drug composite and preparation method thereof
CN105012275B (en) * 2015-08-20 2018-03-27 广东安诺药业股份有限公司 Indapamide slow release agent preparation method
CN111150713B (en) * 2018-11-07 2023-02-10 珠海润都制药股份有限公司 Indapamide capsule and preparation method thereof
CN112370433A (en) * 2020-12-07 2021-02-19 石家庄市华新药业有限责任公司 Indapamide sustained release tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2123293A (en) * 1982-07-09 1984-02-01 Adir Antihypertensive composition containing indapamide and a thiachroman
DE3602304A1 (en) * 1985-02-05 1986-08-07 Sandoz-Patent-GmbH, 79539 Lörrach Pharmaceutical formulations containing 3-aminopropoxyindoles which are optionally combined with a diuretic, and the use thereof
EP0519820A1 (en) * 1991-06-18 1992-12-23 Adir Et Compagnie Matrixtablet for the sustained release of indapamide after oral administration
EP1057479A1 (en) * 1994-12-14 2000-12-06 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8600137A (en) 1985-02-05 1986-09-01 Sandoz Ag PHARMACEUTICAL PREPARATIONS CONTAINING, WHEN DESIRED, COMBINED WITH 3-AMINOPROPOXYINDOLS DIURETICALLY AND METHODS FOR USING THESE PREPARATIONS.
IT1282576B1 (en) * 1996-02-06 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES
US6077534A (en) * 1997-09-02 2000-06-20 Klinge Pharma Gmbh Production of pharmaceutical formulations for treatment of edema and venous disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2123293A (en) * 1982-07-09 1984-02-01 Adir Antihypertensive composition containing indapamide and a thiachroman
DE3602304A1 (en) * 1985-02-05 1986-08-07 Sandoz-Patent-GmbH, 79539 Lörrach Pharmaceutical formulations containing 3-aminopropoxyindoles which are optionally combined with a diuretic, and the use thereof
EP0519820A1 (en) * 1991-06-18 1992-12-23 Adir Et Compagnie Matrixtablet for the sustained release of indapamide after oral administration
EP1057479A1 (en) * 1994-12-14 2000-12-06 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAMIEN, GERARD ET AL: "Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg", CLINICAL PHARMACOKINETICS (1999), 37(SUPPL. 1), 13-19, XP009004369 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005074884A2 (en) * 2004-01-30 2005-08-18 Krka, Tovarna Zdravil, D.D. Novo Mesto Sustained release pharmaceutical composition of indapamide
DE102004005009A1 (en) * 2004-01-30 2005-09-01 Krka Tovarna Zdravil, D.D. Delayed release pharmaceutical composition of indapamide
WO2005074884A3 (en) * 2004-01-30 2005-12-08 Krka Tovarna Zdravil D D Novo Sustained release pharmaceutical composition of indapamide
EA011810B1 (en) * 2004-01-30 2009-06-30 Крка, Товарна Здравил, Д.Д. Ново Место Sustained release pharmaceutical composition of indapamide
EP1669062A1 (en) 2004-12-07 2006-06-14 Les Laboratoires Servier Extended release indapamide tablets and their process of manufacture
WO2006069705A1 (en) * 2004-12-23 2006-07-06 Merckle Gmbh Directly pressed indapamide tablets with delayed release of the active substance

Also Published As

Publication number Publication date
DE60220551D1 (en) 2007-07-19
EP1517683B1 (en) 2007-06-06
PL354823A1 (en) 2004-01-12
EP1517683A1 (en) 2005-03-30
ATE363903T1 (en) 2007-06-15
US20050202086A1 (en) 2005-09-15
DE60220551T2 (en) 2008-02-07
PL193976B1 (en) 2007-04-30
US7553499B2 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
EP2898899B1 (en) Disintegrating particle composition containing acid-type carboxymethylcellulose and crystalline cellulose, and orally disintegrating tablet containing said composition
AU764516B2 (en) Core tablet for controlled release of gliclazide after oral administration
JP5553452B2 (en) Pharmaceutical composition comprising brivaracetam
RO118563B1 (en) Dosed oral composition with instantaneous decomposition, and process for obtaining the same
EP2832350A1 (en) Method for producing disintegrating particulate composition comprising acid-type carboxymethylcellulose, disintegrating particulate composition comprising acid-type carboxymethylcellulose, and orally disintegrating tablet including disintegrating particulate composition comprising acid-type carboxymethylcellulose
WO2008144730A2 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
US5888542A (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine after administration by the oral route
US7553499B2 (en) Sustained release tablet containing indapamide
KR102395687B1 (en) Solid preparations containing tofogliflozin and process of producing the same
KR20200028796A (en) A pharmaceutical composition with an improved stability
JP2009513530A5 (en)
KR101197277B1 (en) Oral Solid Preparation For Treatment And Prevention Of Tuberculosis
US6413541B1 (en) Disintegrating tablet in oral cavity and production thereof
AU2002224011B2 (en) A pharmaceutical composition for controlled release of a beta-lactam antibiotic
JPH08310969A (en) Solid pharmaceutical composition and its preparation
EP0319074B1 (en) Pharmaceutical composition and process for its preparation
EP3911305B1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
KR101175816B1 (en) Sustained release tablet for oral use
US20010046990A1 (en) Pharmaceutical composition and the process for its preparation
KR101244627B1 (en) Composition for oral disitegrating tablets comprising olanzapine, and tablets manufactured therefrom
JPH11349475A (en) Intraoral disintegrant and its production
US20020183308A1 (en) Benazepril Hydrochloride tablet formulations
JP2002173428A (en) Clarithromycin tablet and method for producing the same
KR20110127017A (en) Oral solid composite comprising valsartan
WO2004014356A1 (en) Solid compositions comprising gabapentin having improved stability

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BA EE HR HU LT LV MK RU SI UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002765720

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002765720

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10518386

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002765720

Country of ref document: EP